Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03644251 · ClinicalTrials.gov registry record · NA
FLO for Discogenic Pain
A NA study, sponsored by BioTissue Holdings.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT03644251: Clinical Trial NA study, sponsored by BioTissue Holdings.
NCT03644251 is a NA study that was terminated before completion, run by BioTissue Holdings. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03644251, a NA study, was terminated before completion, sponsored by BioTissue Holdings.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Discogenic pain is pain originating from a damaged vertebral disc and be caused by inflammation, dehydration of the nucleus pulposus, decreased disc height, annular tears and impaired mechanical function of the disc.Non-operative treatment may include traction, steroid therapy, methylene blue injection and ablative therapy. However, there are few high quality studies evaluating these treatments for reducing discogenic low back pain and most clinical trials failed to detect significant differences between treatments and placebo therapies. Hence, there remains an unmet clinical need.
Primary Outcome
0 to 100mm, 100mm worst pain
Interventions
- OTHER amniotic and umbilical cord matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-08-13 |
| Est. Completion | 2019-03-04 |
| Phase | NA |
Why NCT03644251 stopped before completion
NCT03644251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which amniotic and umbilical cord matrix is the first listed.
NCT03644251 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03644251 about?
NCT03644251 is a clinical study titled "FLO for Discogenic Pain". Discogenic pain is pain originating from a damaged vertebral disc and be caused by inflammation, dehydration of the nucleus pulposus, decreased disc height, annular tears and impaired mechanical function of the disc.Non-operative treatment may include traction, steroid therapy, methylene blue inject...
What is the current status of trial NCT03644251?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2018-08-13. Estimated completion is 2019-03-04.
What interventions are being tested in trial NCT03644251?
The interventions under investigation include: amniotic and umbilical cord matrix (OTHER).
Who is sponsoring clinical trial NCT03644251?
This trial is sponsored by BioTissue Holdings, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03644251's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI